N/A
Manufactured by BioDelivery Sciences International Inc
15,869 FDA adverse event reports analyzed
Last updated: 2026-04-15
BUPRENORPHINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by BioDelivery Sciences International Inc. The most commonly reported adverse reactions for BUPRENORPHINE HYDROCHLORIDE include DEPENDENCE, OVERDOSE, DEATH, ILL-DEFINED DISORDER, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BUPRENORPHINE HYDROCHLORIDE.
Out of 7,124 classified reports for BUPRENORPHINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 15,869 FDA FAERS reports that mention BUPRENORPHINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEPENDENCE, OVERDOSE, DEATH, ILL-DEFINED DISORDER, DRUG INEFFECTIVE, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list BioDelivery Sciences International Inc in connection with BUPRENORPHINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.